- Home
- GLUE vs ROG Comparison
GLUE vs ROG Comparison
Compare GLUE & ROG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GLUE | ROG |
|---|---|---|
| Founded | 2019 | 1832 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | 2021 | 1994 |
Fundamental Metrics
Financial Performance| Metric | GLUE | ROG |
|---|---|---|
| Price | $18.74 | $131.88 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $32.00 | ★ $133.00 |
| AVG Volume (30 Days) | ★ 644.3K | 257.9K |
| Earning Date | 05-08-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.25 |
| Revenue | $123,672,000.00 | ★ $879,091,000.00 |
| Revenue This Year | N/A | $7.64 |
| Revenue Next Year | $2.45 | $6.09 |
| P/E Ratio | ★ $72.42 | $524.68 |
| Revenue Growth | ★ 63.54 | 7.07 |
| 52 Week Low | $3.90 | $61.17 |
| 52 Week High | $25.77 | $144.46 |
Technical Indicators
Market Signals| Indicator | GLUE | ROG |
|---|---|---|
| Relative Strength Index (RSI) | 49.76 | 51.41 |
| Support Level | $18.51 | $77.11 |
| Resistance Level | $21.04 | $144.46 |
| Average True Range (ATR) | 1.02 | 5.38 |
| MACD | -0.24 | -1.62 |
| Stochastic Oscillator | 33.59 | 21.92 |
Price Performance
Historical ComparisonAbout GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).
About ROG Rogers Corporation
Rogers Corporation designs develop and manufacture engineered materials and components for sale to original equipment manufacturers and component suppliers. The firm operates in three business segments: Advanced Electronics Solutions, which manufactures circuit materials for applications in communications infrastructure, automotive, and consumer electronics markets; elastomeric material solutions, which provide cushioning, sealing, and impact protection in automotive, transportation, and construction applications; and Other, which consists of elastomer components for applications in the general industrial market, as well as elastomer floats for level sensing in fuel tanks, motors, and storage tanks applications in the general industrial and automotive markets.